Your browser doesn't support javascript.
loading
Outcomes following management of squamous cell carcinoma of the scalp: A retrospective series of 235 patients treated at the Peter MacCallum Cancer Centre.
Estall, Vanessa; Allen, Angela; Webb, Angela; Bressel, Mathias; McCormack, Chris; Spillane, John.
Afiliação
  • Estall V; Liverpool Hospital Cancer Therapy Centre, Sydney, New South Wales, Australia.
  • Allen A; University of Melbourne, Melbourne, Victoria, Australia.
  • Webb A; Waikato Regional Cancer Centre, Hamilton, New Zealand.
  • Bressel M; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • McCormack C; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Spillane J; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Australas J Dermatol ; 58(4): e207-e215, 2017 Nov.
Article em En | MEDLINE | ID: mdl-27283245
BACKGROUND: Squamous cell carcinoma of the scalp is a common clinical problem in an aging population. Despite its high incidence, little has been documented regarding treatment or outcomes. METHODS: We retrospectively analysed 235 cases treated with curative intent at Peter MaCallum Cancer Centre between 1998 and 2010. The cohort was analysed for its characteristics, management, survival and prognostic factors. RESULTS: The patients were primarily male (88%) with a median age of 79 years (range 53-98 years). There was a high proportion of immunosuppressed patients (29%) and stage T2 (48%) tumours. Management included surgery (45%), radiotherapy (28%) and surgery and adjuvant radiotherapy (26%). Median follow up from treatment was 4.5 years. Estimated 5-year overall survival (OS), disease-specific survival and progression-free survival (PFS) were 59, 94 and 51%, respectively. The 5-year cumulative incidence of local and regional relapse was 11 and 7%, respectively. There were four patients who developed distant metastases and died of their disease. Statistically significant prognostic factors identified for poor outcomes for OS and PFS were T2 stage (hazard ratio [1.7 and 2.1) and immunosuppression (HR 3.3 and 3.4). CONCLUSIONS: We conclude the presence of immunosuppression and T2 stage is prognostic for survival. Further research to establish treatment principles is warranted.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Couro Cabeludo / Neoplasias Cutâneas / Carcinoma de Células Escamosas / Neoplasias de Cabeça e Pescoço / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Couro Cabeludo / Neoplasias Cutâneas / Carcinoma de Células Escamosas / Neoplasias de Cabeça e Pescoço / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2017 Tipo de documento: Article